Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,353.34 90.78 0.56%
S&P 500 1,849.84 6.86 0.37%
NASDAQ 4,055.72 21.56 0.53%
Ticker Volume Price Price Delta
STOXX 50 3,123.80 32.28 1.04%
FTSE 100 6,568.86 27.25 0.42%
DAX 9,264.04 90.33 0.98%
Ticker Volume Price Price Delta
NIKKEI 14,417.68 420.87 3.01%
TOPIX 1,166.55 30.46 2.68%
HANG SENG 22,696.01 24.75 0.11%

Keryx Biopharmaceuticals' Zerenex(TM) (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at



Keryx Biopharmaceuticals' Zerenex(TM) (Ferric Citrate Coordination Complex)
Data Selected for Oral and Poster Presentations at the American Society of
Nephrology's Kidney Week 2013

NEW YORK, Oct. 17, 2013 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc.
(Nasdaq:KERX) today announced that abstracts highlighting Zerenex™ (ferric
citrate coordination complex), the Company's drug candidate for the treatment
of elevated serum phosphorus levels, or hyperphosphatemia, in patients with
chronic kidney disease (CKD) on dialysis, have been selected for oral and
poster presentations during the American Society of Nephrology (ASN) Kidney
Week 2013 annual meeting. This annual meeting of the ASN will be held in
Atlanta, Georgia, from November 5-10, 2013.

Summary of Zerenex™ (ferric citrate coordination complex) Data Presentations:

ORAL PRESENTATION:

Saturday, November 9th:

Abstract#: SA-OR083
- Title: Ferric Citrate, a Phosphate Binder, Increases Iron Stores but Is Not
Associated with Evidence of the Malnutrition-Inflammation-Cachexia Syndrome
- Session Name: Dialysis: Anemia, Inflammation, Malnutrition, and Metabolism
- Presentation Time: 5:30pm

CLINICAL POSTER PRESENTATIONS:

Thursday, November 7th:

Abstract #: TH-PO521
- Title: Ferric Citrate as a Phosphate Binder Reduces IV Iron and
Erythropoietin Stimulating Agent (ESA) Use
- Session Name: Dialysis: Anemia, Inflammation, Malnutrition, & Metabolism - I
- Presentation Time: 10:00am

Saturday, November 9th:

Abstract #: SA-PO382
- Title: Achieved Iron Stores and Clinical Outcomes in a Trial of Ferric
Citrate as a Phosphate Binder
- Session Name: Dialysis: Anemia, Inflammation, Malnutrition, & Metabolism -
II
- Presentation Time: 10:00am

Abstract #: SA-PO540
- Title: Ferric Citrate as a Phosphate Binder Has a Safety Profile Similar to
Sevelamer Carbonate and Calcium Acetate
- Session Name: Mineral Disease: CKD-MBD - II
- Presentation Time: 10:00am

Abstract #: SA-PO542
- Title: Ferric Citrate Binds Phosphorus, Delivers Iron, and Reduces IV Iron
and Erythropoietic Stimulating Agent Use in End-Stage Renal Disease
- Session Name: Mineral Disease: CKD-MBD - II
- Presentation Time: 10:00am

Abstract #: SA-PO543
- Title: Impact of Ferric Citrate, an Oral Phosphate Binder, on Mineral and
Bone Metabolism Markers in Dialysis
- Session Name: Mineral Disease: CKD-MBD - II
- Presentation Time: 10:00am

In addition, one abstract from the Company's Japanese partner for Zerenex,
Japan Tobacco, Inc., relating to its Phase 3, multicenter, randomized,
double-blind, placebo-controlled study in non-dialysis dependent Japanese
patients with CKD, has also been accepted for poster presentation during the
annual meeting:

Abstract #: SA-PO544
- Title: The Effect of JTT-751 (Ferric Citrate Hydrate) on Phosphorus and
FGF-23 in Chronic Kidney Disease
- Session Name: Mineral Disease: CKD-MBD - II
- Presentation Date/Time: Saturday, November 9^th, 10:00am

The above abstracts are currently available online for viewing through the ASN
website at: http://www.asn-online.org/education/kidneyweek/archives/.

Keryx holds a worldwide license (except for certain Asian Pacific countries)
to Zerenex (ferric citrate coordination complex) from Panion & BF Biotech,
Inc. The Japanese rights are sublicensed by Keryx to Japan Tobacco Inc. and
Torii Pharmaceutical Co., Ltd.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important pharmaceutical products for the
treatment of renal disease. Keryx is developing Zerenex (ferric citrate
coordination complex), an oral, ferric iron-based compound that has the
capacity to bind to phosphate and form non-absorbable complexes. Keryx has
completed a U.S.-based Phase 3 clinical program for Zerenex for the treatment
of hyperphosphatemia (elevated phosphate levels) in patients with chronic
kidney disease on dialysis, conducted pursuant to a Special Protocol
Assessment (SPA) agreement with the Food and Drug Administration (FDA), and
the Company's New Drug Application is currently under review by the FDA.  The
Marketing Authorization Application filing with the European Medicines Agency
(EMA) is pending submission.  Zerenex is also in Phase 2 development in the
U.S. for the management of elevated phosphorus and iron deficiency in anemic
patients with Stages 3 to 5 non-dialysis dependent chronic kidney disease. In
addition, Keryx's Japanese partner, Japan Tobacco Inc. and Torii
Pharmaceutical Co., Ltd. has filed its New Drug Application for marketing
approval of ferric citrate in Japan for the treatment of hyperphosphatemia in
patients with chronic kidney disease. Keryx is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly those
relating to the results of clinical trials, the clinical benefits to be
derived from Zerenex (ferric citrate coordination complex), regulatory
submissions and the timing of any such review, approvals, the commercial
opportunity and competitive positioning, and any business prospects for
Zerenex, may be forward-looking statements that involve a number of risks and
uncertainties. For those statements, we claim the protection of the safe
harbor for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. Among the factors that could cause our actual
results to differ materially are the following: acceptance of the NDA filing
does not represent final evaluation of the adequacy of the data submitted in
the NDA; whether the FDA will complete its review of the NDA on a timely
basis; the risk that the FDA, EMA, and Japanese Ministry of Health, Labour and
Welfare ultimately deny approval of the U.S. NDA, MAA and Japanese NDA,
respectively; the risk that SPAs are not a guarantee that the FDA will
ultimately approve a product candidate following filing acceptance; whether
the FDA and EMA will concur with our interpretation of our Phase 3 study
results, supportive data, or the conduct of the studies; whether, Zerenex, if
approved, will be successfully launched and marketed; and other risk factors
identified from time to time in our reports filed with the Securities and
Exchange Commission. Any forward-looking statements set forth in this press
release speak only as of the date of this press release. We do not undertake
to update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release and prior
releases are available at www.keryx.com. The information on our website, and
on the ASN website, is not incorporated by reference into this press release
and is included as an inactive textual reference only.

CONTACT: KERYX CONTACT:
         Lauren Fischer
         Director - Investor Relations
         Keryx Biopharmaceuticals, Inc.
         Tel: 212.531.5965
         E-mail: lfischer@keryx.com

Keryx Logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement